Published in Cytotherapy on April 15, 2011
Nanoparticles and their potential for application in bone. Int J Nanomedicine (2012) 0.89
Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int (2013) 0.84
Comparative in vitro study on magnetic iron oxide nanoparticles for MRI tracking of adipose tissue-derived progenitor cells. PLoS One (2014) 0.81
Development of a simple procedure for the treatment of femoral head osteonecrosis with intra-osseous injection of bone marrow mesenchymal stromal cells: study of their biodistribution in the early time points after injection. Stem Cell Res Ther (2015) 0.77
Imaging the intracellular degradation of biodegradable polymer nanoparticles. Beilstein J Nanotechnol (2014) 0.77
Internalization of nanopolymeric tracers does not alter characteristics of placental cells. J Cell Mol Med (2016) 0.75
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One (2008) 5.91
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood (2004) 4.66
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol (2001) 4.54
Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology (2003) 3.72
Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells (2005) 2.80
Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells (2009) 2.57
Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood (2006) 2.49
Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A (1999) 2.42
Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke (2008) 2.18
In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab (2002) 1.99
Applicability and limitations of MR tracking of neural stem cells with asymmetric cell division and rapid turnover: the case of the shiverer dysmyelinated mouse brain. Magn Reson Med (2007) 1.88
Transferrin receptor upregulation: in vitro labeling of rat mesenchymal stem cells with superparamagnetic iron oxide. Radiology (2007) 1.79
Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed (2006) 1.58
Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation (2003) 1.55
Poly(L-lysine)-modified iron oxide nanoparticles for stem cell labeling. Bioconjug Chem (2008) 1.52
Mesenchymal stem cells for clinical application. Vox Sang (2009) 1.50
Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med (2009) 1.49
Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol (2006) 1.44
Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. Macromol Biosci (2008) 1.44
Universal cell labelling with anionic magnetic nanoparticles. Biomaterials (2008) 1.35
Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins. Blood (2007) 1.34
Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng (2008) 1.31
miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol (2009) 1.31
R2 and R2* mapping for sensing cell-bound superparamagnetic nanoparticles: in vitro and murine in vivo testing. Radiology (2007) 1.31
Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials (2006) 1.30
Prospective isolation and global gene expression analysis of the erythrocyte colony-forming unit (CFU-E). Blood (2004) 1.26
A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn Reson Med (2008) 1.23
Development of biodegradable electrospun scaffolds for dermal replacement. Biomaterials (2008) 1.19
Human bone-marrow-derived mesenchymal stem cells: biological characteristics and potential role in therapy of degenerative diseases. Cell Tissue Res (2007) 1.15
Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability. Cytotherapy (2009) 1.14
Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res (2008) 1.12
Stem cell activity of human side population and alpha6 integrin-bright keratinocytes defined by a quantitative in vivo assay. Stem Cells (2006) 1.11
Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol (2008) 1.10
Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy. Isr Med Assoc J (2009) 1.06
The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J Cell Physiol (2009) 1.04
In vivo MRI stem cell tracking requires balancing of detection limit and cell viability. Cell Transplant (2009) 1.03
Mesenchymal stem cell-based cartilage tissue engineering: cells, scaffold and biology. Cytotherapy (2004) 1.03
In vitro labeling and MRI of mesenchymal stem cells from human umbilical cord blood. Magn Reson Imaging (2006) 1.02
The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy (2009) 1.01
Durable mesenchymal stem cell labelling by using polyhedral superparamagnetic iron oxide nanoparticles. Chemistry (2009) 1.01
Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res (2009) 0.99
Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study. Contrast Media Mol Imaging (2008) 0.99
The use of clinically approved small particles of iron oxide (SPIO) for labeling of mesenchymal stem cells aggravates clinical symptoms in experimental autoimmune encephalomyelitis and influences their in vivo distribution. Cell Transplant (2008) 0.94
Cellular uptake behavior of unfunctionalized and functionalized PBCA particles prepared in a miniemulsion. Macromol Biosci (2007) 0.91
Poly-L-lactic acid: an overview. J Drugs Dermatol (2006) 0.87
Monitoring stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents. Acad Radiol (2002) 0.86
The mechanism of iron release from the transferrin-receptor 1 adduct. J Mol Biol (2006) 0.85
Inhibition of transferrin receptor 1 transcription by a cell density response element. Biochem J (2005) 0.82
Preparation of biodegradable polymer nanoparticles by miniemulsion technique and their cell interactions. Macromol Biosci (2008) 0.80
Synthesis of fluorescent polyisoprene nanoparticles and their uptake into various cells. Macromol Biosci (2008) 0.79
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell (2012) 2.60
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Multienergy photon-counting K-edge imaging: potential for improved luminal depiction in vascular imaging. Radiology (2008) 2.27
Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood (2002) 2.24
Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther (2010) 2.15
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol (2003) 1.76
Interaction of nanoparticles with cells. Biomacromolecules (2009) 1.73
A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells. Blood (2014) 1.68
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2013) 1.68
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano (2011) 1.66
A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. Blood (2013) 1.61
Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood (2006) 1.58
Computed tomography in color: NanoK-enhanced spectral CT molecular imaging. Angew Chem Int Ed Engl (2010) 1.57
Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur J Immunol (2011) 1.54
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene (2002) 1.53
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 1.52
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion (2010) 1.49
Motion-compensated and gated cone beam filtered back-projection for 3-D rotational X-ray angiography. IEEE Trans Med Imaging (2006) 1.45
Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. Macromol Biosci (2008) 1.44
High-resolution ZTE imaging of human teeth. NMR Biomed (2012) 1.43
Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol (2011) 1.42
Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol (2010) 1.40
Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med (2013) 1.37
GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One (2012) 1.33
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood (2013) 1.30
Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials (2006) 1.30
CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica (2010) 1.30
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica (2012) 1.29
Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. BMC Surg (2010) 1.28
Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res (2013) 1.27
Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. Cytotherapy (2013) 1.27
Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica (2010) 1.27
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol (2009) 1.24
Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation (2006) 1.21
Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood (2012) 1.20
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell (2012) 1.16
In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med (2007) 1.16
CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol (2008) 1.15
Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol (2013) 1.13
Microarray-based understanding of normal and malignant plasma cells. Immunol Rev (2006) 1.12
Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat Nanotechnol (2013) 1.12
Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials (2010) 1.12
Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages. ACS Nano (2011) 1.12
Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J Immunol (2009) 1.12
Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol (2011) 1.11
Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol (2008) 1.10
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials (2010) 1.08
mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J Cell Mol Med (2007) 1.08
Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med (2002) 1.08
Novel approaches to polymer blends based on polymer nanoparticles. Nat Mater (2003) 1.07
Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood (2012) 1.06
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One (2011) 1.06
Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol (2011) 1.05
Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues. Transfus Med Hemother (2008) 1.04
BSA adsorption on differently charged polystyrene nanoparticles using isothermal titration calorimetry and the influence on cellular uptake. Macromol Biosci (2011) 1.03
Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther (2013) 1.03
Feasibility of ultra-short echo time (UTE) magnetic resonance imaging for identification of carious lesions. Magn Reson Med (2011) 1.03
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis (2010) 1.02
Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica (2012) 1.01
Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res (2009) 0.99
Homing of Mesenchymal Stem Cells. Transfus Med Hemother (2008) 0.97
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med (2015) 0.97